Navigation Links
New Study Provides Benchmarks for Optimizing Marketing Staff Levels to Drive Growth
Date:2/5/2009

CHAPEL HILL, N.C., Feb. 5 /PRNewswire/ -- In today's tough economy, maintaining operational efficiencies remains key, even while focusing on strategy and tactics to drive growth and profitability. In an effort to better understand the resources dedicated by biopharmaceutical companies to support marketing operations, a recent benchmark study was conducted by Best Practices, LLC, with insights available in the newly published report, "Benchmarks for Optimizing Marketing Staff Levels to Drive Growth." Data from this study were collected from more than sixty biopharma marketing leaders.

Benchmark data shares insights from a number of critical areas, including:

-- Staffing and productivity levels utilized across healthcare business models

    -- Growth and profit margin levels across biopharma portfolios
    -- Strategic and tactical activities that drive profitability & growth

The metrics shared in this study, segmented across pharma/biotech, medical devices and generic products, were gathered from across the biopharma industry including such companies as Abbott, Amgen, Baxter, Johnson & Johnson, Novartis, Pfizer, Roche, and Sanofi-Aventis.

    Key metrics found in the report include:
    -- Number of Products Supported Per Tactical Marketing FTE
    -- Number of Strategic Marketing FTEs per $100 Million
    -- Time & Activity Benchmarks for Strategic Marketing Staff
    -- Strategic Marketing Staff Benchmarks Across Key Activities
    -- Tactical Marketing Staff Benchmarks Across Key Activities

For more information on this report, contact Ben Gregory at bgregory@best-in-class.com or (919) 767-9160. To access the full report or download a complimentary copy of the report summary, go to www.best-in-class.com/rr977.htm.

ABOUT BEST PRACTICES, LLC

Best Practices, LLC, conducts work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies. For more than 15 years, our highly credentialed research staff has conducted primary research exclusively for our Fortune 500 client base.


'/>"/>
SOURCE Best Practices, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study
2. Results From Phase 2 Clinical Study of 6R-BH4 in Peripheral Arterial Disease Not Statistically Significant
3. New Study Provides Benchmarks for Winning Brand Team Management
4. New Study Shares Insights for Competitive Intelligence Policies, Ethics and Data Collection
5. New Multi-Center Study Finds Masimo SET Pulse Oximetry Screening Significantly Improves Detection of Congenital Heart Disease in Newborns
6. Epilepsia Study Demonstrates New Add-on Antiepileptic Drug Vimpat(R) (lacosamide) Significantly Reduces Partial-Onset Seizures in Adults With Epilepsy
7. Rib-X Pharmaceuticals Announces Positive Phase 2 Study Results for Delafloxacin and a $25 Million Financing
8. Clinical Research Study Focuses on Little Known Behavioral Changes Related to Parkinsons Disease
9. Cardiovascular Side Effects of Pioglitazone and Rosiglitazone Linked to Vascular and Energy Pathways by Genomas Clinical Study
10. Genomic Health Announces Commencement of QUASAR Clinical Validation Study for Oncotype DX(R) Colon Cancer Assay
11. Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... 23, 2016 , ... UAS LifeSciences, one of the leading ... UP4™ Probiotics, into Target stores nationwide. The company, which has been manufacturing high ... its list of well-respected retailers. This list includes such fine stores as Whole ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... 23, 2016 Houston Methodist Willowbrook Hospital ... Sports Association to serve as their official health ... Methodist Willowbrook will provide sponsorship support, athletic training ... association coaches, volunteers, athletes and families. ... Sports Association and to bring Houston Methodist quality ...
(Date:6/23/2016)... June 23, 2016  The Prostate Cancer Foundation (PCF) is pleased ... and faster cures for prostate cancer. Members of the Class of 2016 were ... Read More About the Class of 2016 PCF Young ... ... ...
Breaking Biology Technology:
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
(Date:4/15/2016)... 2016 Research and Markets has ... Market 2016-2020,"  report to their offering.  , ... ,The global gait biometrics market is expected to ... period 2016-2020. Gait analysis generates multiple ... used to compute factors that are not or ...
(Date:3/29/2016)... 29, 2016 LegacyXChange, Inc. (OTC: ... and SelectaDNA/CSI Protect are pleased to announce our successful ... a variety of writing instruments, ensuring athletes signatures against ... collectibles from athletes on LegacyXChange will be assured of ... DNA. Bill Bollander , CEO states, ...
Breaking Biology News(10 mins):